Challenges, Unmet Needs, and the Future of Advanced Urothelial Carcinoma Management
A key opinion leader addresses the persistent challenges and unmet needs in the management of advanced urothelial carcinoma, while offering their insight into the future direction and potential advancements within this rapidly evolving field of oncology.
EP: 1.Overview a 73-Year-Old Man with Metastatic Urothelial Carcinoma Case
EP: 2.Metastatic Urothelial Carcinoma: Optimizing Care Through Multidisciplinary Teamwork
EP: 3.Examining Molecular Testing in Metastatic Urothelial Cancer: Present and Future
EP: 4.Expert Insights: Biomarker Evaluation and Timing in Management of Patients with mUC
EP: 5.Navigating First-Line Treatment Choices for Metastatic Urothelial Carcinoma
EP: 6.Navigating Later-Line Therapies for Progressive Urothelial Cancer
EP: 7.Managing a Novel Therapeutic Option for mUC Treatment
EP: 8.Challenges, Unmet Needs, and the Future of Advanced Urothelial Carcinoma Management
- What are the remaining challenges and unmet needs in advanced urothelial carcinoma?
- What are some promising approaches currently under study, and your hopes/expectations for treatment over the next 5-10 years?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
